Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Supplementation for ROP Prevention in VLBW Infants
NCT02486042Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Mar 2014
- Primary completion
- Dec 2019
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in retinopathy of prematurity (ROP) comparing Standard of Care with Omegaven (2 arms). Primary endpoint: Changes in mRNA Expression in Blood of STAT3, PPAR-gamma, and STC-1. Started Mar 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02486042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486042.